Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...

Breast cancer has a survival rate of over 95% when detected early, but this drops sharply to around 40% in cases of ...

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Currently, ligand-mediated RNAi conjugates lead the market. However, future growth is anticipated in ligand-attached anti-sense therapies. In terms of targeting ligand types, peptides currently hold a ...

In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...

Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

The ADC market offers significant growth opportunities driven by the rising cancer incidence and demand for targeted therapies, which improve efficacy and reduce toxicity. Advancements in precision ...

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...